loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations
IPOLogoImag

BIO MEDICA LABORATORIES IPO

UPCOMING

IPO Details

21th May 2026
25th May 2026
1,000
₹ 2,30,400
₹ 132-139
₹ 52 Crore

Issue timeline

  • 21-25 May 2026
  • 26-May-2026
  • 27-May-2026
  • 27-May-2026
  • 29-May-2026

Subscription Status

Shareholder -
Qualified Institutional Buyers -
Non-Institutional Investor -
Retail Individual Investor -
Employee -
Total -

About Company

Bio Medica Laboratories Limited is a B2B contract manufacturer specializing in pharmaceutical parenteral formulations. The company produces a diverse portfolio of ethical, generic, and over-the-counter (OTC) medications in injectable formats, catering to both human and veterinary healthcare needs. Its product line features 58 liquid injectables and 15 dry powder injectables, available in both single-dose and multi-dose formats.

Operating from two manufacturing facilities in Indore, Madhya Pradesh, the company produces unpatented formulations strictly based on client specifications and publicly available formulas. It holds both GMP and GLP certifications from the Food & Drugs Administration, Madhya Pradesh, supported by an advanced in-house laboratory equipped with high-tech testing instruments like HPLC and Gas Chromatography. Benefiting from India's MSME Incentive Scheme 2021, the company allows corporate clients to brand the products as "marketed by" while maintaining stringent, temperature-controlled manufacturing standards until final dispatch.

2015
Pradeep Mehta

Objectives

Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises
Repayment of loan
General corporate purposes

Strengths & Risks

Strengths (4)

Seasoned Leadership: Guided by promoters with over 37 years of pharmaceutical industry experience to drive strategic market growth.

Risks (4)

Client Concentration: Heavy revenue dependence on a few key clients poses a critical risk if a major relationship is lost.

Financials

Industry Overview

  • Robust Macro Growth: The Indian pharmaceutical industry was valued at USD 49.1 billion in FY24 and is projected to expand at a CAGR of 9.53%, reaching USD 84.77 billion by 2030.
  • Surging Injectables Market: Driven by rising cases of oncology, diabetes, and cardiovascular diseases, the domestic injectable drugs segment is forecast to grow from USD 19 billion in 2024 to USD 28.35 billion by 2030, heavily supported by government PLI schemes and bulk drug parks.
  • Diversified Production Mix: Production in FY25 shows a strategic blend of traditional and modern medicine, led by Ayurvedic and Homeopathic formulations (24.8%), Antibiotics and APIs (18.8%), and Anti-retroviral HIV drugs (14%).

Bio Medica Laboratories IPO FAQs

What is the Bio Medica Laboratories IPO opening date?

The Bio Medica Laboratories IPO is scheduled to open for public subscription on May 21, 2026, and close on May 25, 2026.

The price band for Bio Medica Laboratories IPO has been fixed in the range of ₹132 to ₹139 per equity share.

The minimum lot size for Bio Medica Laboratories IPO is 1000, and the minimum amount required for application is ₹2,78,000, with 2 lots being the minimum application size.

The promoters of the company are Mr. Mukesh Mehta and Mr. Pradeep Mehta.

 

The shares are proposed to be listed on the NSE and SME.

View More

*The financials mentioned above are sourced from DRHP/ RHP documents.